| SFDA Approved Use |
PROGESTERONE indicated in adult women.
Oral Route: Gynaecological: - Disorders due to progesterone insufficiency, Particularly: - premenstrual syndrome, - menstrual irregularities with dysovulation or anovulation, - benign breast disorders, - peri-menopause. - treatment of menopause (in addition to oestrogen therapy). - sterility due to luteal failure. Obstetric: - Threatened miscarriage or prevention of repeated miscarriage due to proven luteal insufficiency. - Threatened premature delivery. Vaginal Route: - Subfertility or primary/secondary infertility due to partial or total luteal phase deficiency (in particular: irregular ovulation, supplementation of the luteal phase during in vitro fertilisation, egg donations). - Threat of miscarriage or prevention of recurrent miscarriages due to luteal phase deficiency. - Prevention of a premature singleton birth in women at risk, with a short cervical length of [less or equal] 25 mm measured between weeks 16 and 24 of pregnancy (weeks 18 and 26 of amenorrhoea) |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.